NCT07079228View on ClinicalTrials.gov

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

602

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

September 30, 2030

Conditions
Pancreatic Cancer
Interventions
DRUG

QLS31905

QLS31905 will be administered as an IV infusion.

DRUG

Nab-paclitaxel.

Nab-paclitaxel will be administered as an IV infusion.

DRUG

Gemcitabine

Gemcitabine will be administered as an IV infusion.

DRUG

Placebo for QLS31905

Placebo will be administered as an IV infusion.

DRUG

Nab-paclitaxel.

Nab-paclitaxel will be administered as an IV infusion

DRUG

Gemcitabine

Gemcitabine will be administered as an IV infusion.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY